The miR-29b Byproduct MIRTX Shows Superior Anti-tumor Activity, Compared to miR-29b-3p, in Pancreatic Cancer Cells.
Аннотация
BACKGROUND/AIM: Pancreatic cancer has a poor prognosis, with a 5-year survival rate of only 9%. Thus, there is an urgent need to develop effective cancer therapeutics for this disease. It is expected that nucleic acid therapeutics will be a next-generation cancer treatment. We previously reported that MIRTX - a complementary strand of miR-29b-1-5p (the passenger sequence of miR-29b) - exerts strong anti-tumor effects in colorectal cancer cells. Here we investigated the anti-tumor effects of MIRTX, compared to those of the guide sequence of miR-29b (miR-29b-3p), in pancreatic cancer cells.
MATERIALS AND
METHODS
We evaluated how treatment with MIRTX and miR-29b-3p affected cell proliferation, cell cycle, apoptosis, and invasion in pancreatic cancer cell lines (Panc-1, SUIT-2, and BxPC-3). We also performed RNA-seq and in silico analyses to explore novel target genes of MIRTX.
RESULTS
Compared to miR-29b-3p, MIRTX strongly suppressed cell proliferation and invasion, delayed cell cycle progression, and induced apoptosis in pancreatic cancer cells. RNA-seq and in silico prediction identified the genes encoding cyclin A2, cyclin B2, and NCAPD3 as potential candidate targets of MIRTX.
CONCLUSION
MIRTX is a potential therapeutic miRNA in pancreatic cancer cells.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.